GSK (GSK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,816.00p
   
  • Change Today:
      63.00p
  • 52 Week High: 2,208.00
  • 52 Week Low: 1,620.00
  • Currency: UK Pounds
  • Shares Issued: 4,045.43m
  • Volume: 7,426,853
  • Market Cap: £73,465m
  • RiskGrade: 129
  • Beta: 0.00

GSK Overview

We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of 2030. Our bold ambitions for patients are reflected in commitments to growth and a step-change in performance. We are a company where outstanding people can thrive.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

Financials

Latest F'cast
Div Yield 3.4% 0.0%
Div Cover 2.6 2.5
Op Mrgn 24.3% 28.1%
ROCE 62.0%  
Latest F'cast
P/E 11.4 12.1
PEG 1.4 2.2
Pr/Revenue 2.4 2.6
Pr/Book 5.0  
Latest F'cast
Revenue 4.1% 3.8%
PBT 112.9% 28.5%
EPS 8.0% 4.0%
DPS 8.2% 7.6%

GSK Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-21 24,696.00 3,599.00 90.56p 22.2 n/a -22% 80.00p 4.0%
31-Dec-22 29,324.00 5,628.00 139.70p 10.3 0.2 +54% 44.00p 3.1%
31-Dec-23 30,328.00 6,064.00 155.10p 9.4 0.9 +11% 58.00p 4.0%
31-Dec-24 31,376.00 3,477.00 159.30p 8.5 2.8 +3% 61.00p 4.5%
31-Dec-25 32,667.00 7,401.00 172.00p 10.6 1.3 +8% 66.00p 3.6%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

GSK Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-26 33,908.57 9,512.33 178.96p 9.8 2.4 +4% 71.03p 0.0%
31-Dec-27 35,500.63 10,589.27 189.99p 9.2 1.5 +6% 76.66p 0.0%

Copyright © 2026 FactSet Research Systems Inc. All rights reserved.

GSK Company Announcements

Director/PDMR Shareholding 14-Oct-2026 15:30 RNS
Director/PDMR Shareholding 13-Oct-2026 15:30 RNS
Director/PDMR Shareholding 12-Oct-2026 15:30 RNS

GSK ShareCast News

Berenberg upgrades GSK to 'buy', raises target p... 15-Sep-2026 ShareCast
GSK acquires global rights to multiple myeloma a... 15-Sep-2026 ShareCast
GSK highlights pipeline momentum with Ris‑... 14-Sep-2026 ShareCast

GSK Top Newspaper Links

GSK invests £400m to relocate research headquart... 28-Jul-2026 Times
GSK to buy US cancer treatment firm Nuvalent for... 09-Jun-2026 Guardian
GSK signs £45m deal with UCL offshoot for liver ... 08-Jun-2026 Times

Latest GSK Director Deals

Traded Action Notifier PriceAmountValue
12-Oct-26 Buy Dividends Julie Brown 1,735.50p 1,863 £32,332.36
12-Oct-26 Buy Dividends Luke Miels 1,735.50p 1,413 £24,522.61
09-Oct-26 Buy Dividends Vishal Sikka 3,519.79p 136 £4,786.92

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

GSK Market Data

Currency UK Pounds
Share Price 1,816.00p
Change Today 63.00p
% Change 3.59 %
52 Week High 2,208.00
52 Week Low 1,620.00
Volume 7,426,853
Shares Issued 4,045.43m
Market Cap £73,465m
Beta 0.00
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
77.36% below the market average77.36% below the market average77.36% below the market average77.36% below the market average77.36% below the market average
30% below the sector average30% below the sector average30% below the sector average30% below the sector average30% below the sector average
Price Trend
74.97% above the market average74.97% above the market average74.97% above the market average74.97% above the market average74.97% above the market average
72.09% above the sector average72.09% above the sector average72.09% above the sector average72.09% above the sector average72.09% above the sector average
Income
19.64% above the market average19.64% above the market average19.64% above the market average19.64% above the market average19.64% above the market average
20.00% above the sector average20.00% above the sector average20.00% above the sector average20.00% above the sector average20.00% above the sector average
Growth
39.90% above the market average39.90% above the market average39.90% above the market average39.90% above the market average39.90% above the market average
57.14% below the sector average57.14% below the sector average57.14% below the sector average57.14% below the sector average57.14% below the sector average

What The Brokers Say

Strong Buy 4
Buy 3
Neutral 12
Sell 2
Strong Sell 0
Total 21
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q2 Q1
Ex-Div 13-Aug-26 14-May-26
Paid 08-Oct-26 09-Jul-26
Amount 17.00p 17.00p

Trades for 14-Oct-2026

Time Volume / Share Price
09:00 699,052 @ 1,740.00p
16:38 222 @ 1,816.00p
16:35 2,408 @ 1,816.00p
16:35 2,408 @ 1,816.00p
16:35 2,408 @ 1,816.00p

GSK Key Personnel

CEO Luke Miels

Top of Page